

## **BioInvent's partner ThromboGenics reports Day 150 topline data from phase I/II study of THR-317 in patients with Diabetic Macular Edema**

**Lund, Sweden – 19 July 2018** – BioInvent International AB (OMXS: BINV) partner ThromboGenics NV has today reported Day 150 topline results from a Phase I/II, single-masked, multicentre study (THR-317-001) evaluating the safety and efficacy of 2 dose levels (4 mg and 8 mg) of THR-317 for the treatment of diabetic macular edema (NCT03071068).

The study met its primary endpoint of safety for both the 4 mg and 8 mg doses. Whilst the focus of the study was safety, efficacy was also observed.

For further information on the study, see ThromboGenic's press release of 19 July 2018 ([www.thrombogenics.com](http://www.thrombogenics.com)).

ThromboGenics carries all costs for the development of THR-317 and BioInvent is entitled to five percent of the project's economic value.

### **Notes to editors:**

#### **About BioInvent**

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurios, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. The Company has a strategic research collaboration with Pfizer Inc. and BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is available at [www.bioinvent.se](http://www.bioinvent.se)

### **For further information, please contact:**

Björn Frendéus  
Acting CEO and CSO  
+46 (0) 46 286 25 45  
+46 (0) 708 11 25 45  
[bjorn.frendeus@bioinvent.com](mailto:bjorn.frendeus@bioinvent.com)

#### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263  
Visiting address: Sölvegatan 41  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

*The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this*

*press release.*

*This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.40 p.m. CET, on 19 July, 2018.*